Products

InferOperate Suite
Beijing Infervision Healthcare Medical Technology Co.
Oncology AI
InferOperate Suite is an AI-powered medical imaging software by Infervision, offering automated 3D reconstruction, visualization, and comprehensive surgical planning tools for various procedures, including those for lung, liver, and kidney tumors.

See all 1 product →

About Beijing Infervision Healthcare Medical Technology

Beijing Infervision Healthcare Medical Technology is a leading artificial intelligence (AI) medical technology company focused on empowering physicians with enhanced diagnostic accuracy and improved clinical workflows. The company leverages deep learning and AI technologies to develop comprehensive software platforms that assist across various medical disciplines. These platforms provide advanced medical imaging analysis, aiding in the diagnosis, treatment, and management of a broad spectrum of conditions, including different types of cancers, infectious diseases, cardiovascular diseases, cerebrovascular diseases, and trauma.

Infervision’s product portfolio includes solutions for disease screening and diagnosis (e.g., InferRead® for pulmonary nodules, pneumonia, intracranial hemorrhage, coronary artery disease, and chest fractures), intervention and treatment (e.g., InferOperate® for surgical planning and 3D reconstructions for thorax, liver, and urology), patient health management (InferCare®), and teaching and research initiatives (InferScholar®, InferMartrix, InferEducate). These AI-assisted tools are designed for seamless integration into existing clinical workflows, offering real-time feedback and actionable insights. The goal is to alleviate physician workload, increase diagnostic efficiency and accuracy, and ultimately contribute to better patient outcomes and reduced healthcare costs. Infervision’s products have achieved significant international market access, holding certifications from the US FDA, European CE, Japan PMDA, UK UKCA, and China NMPA, and are utilized in hundreds of medical institutions worldwide.

Focus Areas

AI-assisted medical imaging disease screening and diagnosis intervention and treatment patient management medical research oncology pulmonary diseases cardiovascular diseases cerebrovascular diseases trauma surgical planning

Business Intelligence

Key InvestorsGoldman Sachs Asset Management, Z-Park Fund, CCB Trust, Sequoia Capital, Qiming Venture Partners, CDH Investments, Springhill Fund, AsiaTech Management, TopoScend Capital, Xianghe Capital Co., Advantech Capital LP, Genesis Capital LLC
PartnershipsGE Healthcare, ConcertAI's TeraRecon, Microsoft, NVIDIA, NHS SBS framework, Peking Union Medical College Hospital, Shanghai Changzheng Hospital, Tongji Medical College of HUST in Wuhan, Dalian Zhongshan Hospital, Beijing Tian Tan Hospital, Campus Bio-Medico University Hospital (Italy), Sanford Health
AcquisitionsNone reported.
TechnologyDeep learning, computer vision, AI-powered detection and triage systems, AI application management platform, AI data-mining research platform, AI clinical application platforms, 3D reconstruction, cloud-native/on-premise deployment options
FDA Clearances4 cleared products (estimated)

What Physicians Need to Know

AI-Assisted Medical Imaging & Diagnosis
Infervision offers a comprehensive suite of AI-powered solutions (InferReadu00ae) for rapid and accurate detection and diagnosis across various medical imaging modalities (DR, CT, MRI). This includes identifying lung nodules, pneumonia, intracranial hemorrhage, coronary artery stenosis, and chest fractures. Their AI can provide detailed nodule characteristics (volume, density) and compare with prior studies for tracking changes.
Oncology
Specialized AI tools assist in cancer screening (e.g., lung nodules), diagnosis, and patient management. Infervision's solutions aid in identifying cancerous lymph nodes, tumor assessment (InferCare RECIST), multi-dimensional lesion analysis, cross-timepoint lesion comparison, and generating automated structured reports for oncology workflows.
Pulmonary Diseases
InferReadu00ae CT Lung and DR Chest are core products for lung nodule screening, detection of pneumonia, chronic lung diseases (like emphysema), and chest fractures. The AI helps reduce missed nodules by 35% and reading times by approximately 33% for radiologists.
Cardiovascular Diseases
InferReadu00ae CT Coronary enables vessel segmentation and reconstruction, identifying coronary artery stenosis. They also offer cardiac calcification screening.
Cerebrovascular Diseases
InferReadu00ae CT Stroke provides fast identification and alerts for suspected intracranial hemorrhage (ICH) and assists in determining stroke type (hemorrhagic or ischemic), location, and blood volume, crucial for timely intervention. They have developed 5G mobile stroke units for diagnosis and treatment at the stroke site.
Trauma & Surgical Planning
InferOperateu00ae Suite offers high-precision, fully automated 3D anatomical segmentation and reconstruction within minutes for preoperative planning and intraoperative visualization. This includes planning for thorax, liver, and urology surgeries, aiding in simulating surgical strategies, quantitative lesion analysis, and precise planning of surgical margins. InferReadu00ae CT Bone assists in identifying chest fractures.
Patient Management & Medical Research
InferCareu00ae is designed for patient health management and image follow-up. InferScholaru00ae and InferMatrixu00ae are AI-enabled medical research solutions, allowing physicians with limited coding experience to conduct scientific research through deep-learning analytical tools with a graphical user interface.
Physician Tip

Infervision's AI solutions are designed to significantly enhance physician workflow by reducing reading times (e.g., 33% for CT chest low-dose lung cancer screening), improving diagnostic accuracy (e.g., reducing missed nodules by 35%), and increasing confidence in interpretations. The automated 3D reconstructions for surgical planning provide critical anatomical insights and allow for simulation of surgical strategies, potentially leading to improved patient safety and reduced complications. The systems offer real-time alerts for critical findings, enabling faster triage and intervention, especially in emergency conditions like stroke. Furthermore, their research platforms empower physicians to engage in AI-driven medical research without extensive coding knowledge.

Infervision's products are designed for seamless integration into existing clinical workflows and hospital systems. They are compatible with DICOM compliant medical images and support cross-campus oncology data management through compatibility with DICOM and HL7. Their solutions can be deployed both on-premise and cloud-based environments, offering flexibility. Partnerships with companies like Viz.ai and ConcertAI's TeraRecon further expand their integration capabilities within broader healthcare ecosystems.

Products by Beijing Infervision Healthcare Medical Technology

1 product in the directory

InferOperate Suite
Beijing Infervision Healthcare Medical Technology Co.
Oncology AI
InferOperate Suite is an AI-powered medical imaging software by Infervision, offering automated 3D reconstruction, visualization, and comprehensive surgical planning tools for various procedures, including those for lung, liver, and kidney tumors.

Reviews & Opinions

No web reviews on file yet for Beijing Infervision Healthcare Medical Technology. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Beijing Infervision Healthcare Medical Technology.

Loading videos...

Videos load interactively. If none appear, search YouTube for Beijing Infervision Healthcare Medical Technology →

View all on YouTube

Press & Coverage

Infervision
Infervision Receives FDA Clearance of InferOperate Suite
Infervision received FDA 510(k) clearance for its InferOperate Suite, a surgical planning AI solution, making it cleared in the US, EU, UK, and China. This suite automates 3D model generation for organs and vascular structures, aiding in preoperative planning and intraoperative guidance, particularly for high-risk tumor surgeries.
2025-09
Infervision
Leading the Future of Medical Imaging: InferVision Showcases Global-Ready AI Innovations at RSNA 2025
InferVision showcased new breakthroughs in surgical planning, oncology assessment, and global ecosystem collaboration at RSNA 2025, reaffirming its leadership in AI healthcare. Their InferOperate automatic 3D reconstruction products have achieved regulatory milestones with CE, UKCA, and FDA clearances, enabling full-scale commercial deployment.
2025-12
Infervision
Infervision Receives FDA 510(k) Clearance for Enhanced Features in InferRead CT Lung
Infervision announced FDA 510(k) clearance for enhanced features in its InferReadu00ae Lung CT.AI product, strengthening its position in AI-driven lung nodule detection. This clearance, alongside approvals from European CE, UK UKCA, Japan PMDA, and China NMPA, expands Infervision's global regulatory footprint.
2025-05
Infervision
Infervision's AI Solutions for Chest, Brain, and Heart Secure CE and UKCA Certifications
Infervision's AI-assisted diagnostic solutions for chest, brain, and heart have received dual certification from European MDR CE and UKCA, strengthening its presence in European and UK markets. These certifications cover indications for pulmonary nodules, pneumonia, intracranial hemorrhage, coronary artery disease, and chest fractures.
2024-08
Infervision
Viz.ai and Infervision Partner on AI Solution to Aid in Earlier Detection and Clinical Workup of Lung Cancer
Viz.ai announced a partnership with Infervision to incorporate InferRead Lung CT.AI, Infervision's FDA-cleared AI solution for lung nodule detection, into the Viz.ai ecosystem. This collaboration aims to improve the earlier detection and clinical workup of lung cancer.
2024-04
AuntMinnie
SimonMed to integrate Infervision tech into its facilities
SimonMed Imaging is integrating Infervision's AI-powered InferRead Lung CT.AI technology into its facilities to enhance the identification, 3D characterization, and comparison of pulmonary nodules in CT chest scans.
2024-04
PR Newswire
InferVision Completes Series D2 Financing Round Led by Goldman Sachs Asset Management
InferVision, an AI medical provider, completed its Series D2 financing round led by Goldman Sachs Asset Management, raising approximately US$140 million in total from Series D1 and D2. The funds will be used for R&D, distribution channel expansion, and business development.
2021-08
KrASIA
AI medtech startup InferVision raises USD 139 million in Series D for predictive medicine
Beijing-based medical AI company InferVision completed a Series D round worth RMB 900 million (USD 139 million) from investors including Goldman Sachs, Z-Park Fund, and CCB Trust. The funds will be allocated to research and development and expanding into new overseas markets.
2021-07

Frequently Asked Questions

Infervision's InferReadu00ae product series provides AI-assisted diagnostic solutions for a wide range of conditions, including pulmonary nodules, pneumonia, intracranial hemorrhage (stroke), coronary artery disease, and chest fractures. These solutions aim to enhance diagnostic accuracy and efficiency, covering oncology, pulmonary, cardiovascular, cerebrovascular, and trauma specialties.
Infervision offers the InferOperateu00ae Suite, an AI-powered solution for intervention and treatment, specifically surgical planning. This suite automates high-precision 3D anatomical segmentation and reconstruction within minutes, aiding in preoperative planning and intraoperative visualization for complex procedures involving organs like the lungs, liver, and kidneys.
Infervision's AI solutions have secured multiple international regulatory approvals, including certifications from the US FDA, European MDR CE, UKCA, Japan PMDA, and China NMPA. This broad compliance ensures their products meet stringent quality and safety standards for deployment in major global markets.
Infervision extends its AI capabilities to patient health management through InferCareu00ae, and supports medical research and education with InferScholaru00ae, InferMartrix, and InferEducate. For instance, InferCare RECIST provides AI-powered, standardized tumor assessment for oncology workflows and follow-up.
Infervision has formed strategic partnerships to integrate its AI solutions, such as collaborating with Viz.ai to incorporate InferRead Lung CT.AI into their care coordination platform. They also partner with ConcertAI's TeraRecon to make their lung CT AI available on the Eureka Clinical AI platform, and their solutions are included in frameworks like the UK's National Health Service (NHS).
Established in 2016, Infervision is a Series D company with over $213 million in funding, indicating strong financial stability. The company has a global presence with offices in the US, Europe, and Japan, and its products are used by over 900 healthcare providers in nearly 20 countries, suggesting a robust infrastructure for long-term support.
Infervision offers various pricing options designed to meet diverse needs, though specific models are not publicly detailed. The company emphasizes developing 'workflow friendly' and accurate solutions, suggesting a focus on seamless integration and efficiency for clinicians, with support aimed at improving diagnostic accuracy and reducing reading times.

Related Companies

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]

Healthcare Finance.AI is a company dedicated to leveraging cutting-edge artificial intelligence to optimize healthcare revenue cycles. Their goal is to improve financial outcomes for healthcare providers while simultaneously supporting the industry’s commitment to quality care and efficiency. They aim to achieve this by enhancing healthcare finance through AI innovation, demonstrating increased revenue cycle efficiency, reducing […]

The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]

Imperial College Business School is a global business school that is part of Imperial College London, a top-ranking science-based institution. Established in 2004, the school integrates business and entrepreneurship with technology. Its roots in business education trace back to 1955 with an operational research/management science course. The school is triple-crown accredited (AACSB, AMBA, EQUIS), placing […]

Columbia University, through its online learning initiative ColumbiaX on edX, offers a range of courses, including those focused on healthcare AI. The university is a global leader in research, teaching, and public impact, consistently ranked among top universities. Their online offerings reflect a commitment to academic excellence and expanding access to high-quality education worldwide. For […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.